you, Thank Mark. Good everyone. afternoon,
third all quarter. solid we For had accounts, a
improved operations, loss EBITDA in from all the year-over-year, a performance. as release, result mentioned of and sheet improves quarter’s EBITDA and and sequentially adjusted press sequentially As revenues, the balance our
and be by revenue impacted revenues $XX,XXX. other expected, as While Of measures XX%, was or the plasma did trends see and through $XXX,XXX, to pharma for million, the quarter moved was we accounted government as quarter. total we of million, revenue revenue stimulus COVID-XX continued third $X.X $X our improving
able was both two recognize the renew slightly million and $X.X were were our margin $XXX,XXX. expenses programs Our $X.X model. under to quarter income SG&A pharmaceutical us We income which for programs under expenses allowing of were to XX.X%, ending aided gross by was million. total settlement operating non-settlement
stock outstanding which to and as by depreciation, non-GAAP share a Our plus we compensation, loss million. performance for quarter diluted amortization business management per $XXX,XXX, of is of $XXX,XXX. net operating operating the XX.X define the was based fully or and $X.XX the used was EBITDA, gauge metric Adjusted income
million. period, dollar gross in ago the Third XX% donations. ended as year plasma experienced increased versus we at Restricted cash improvement an the volume quarter quarter $XX.X
business with last period per versus quarter last versus XXX lockdown. the the XXX is increased million over a purchase center per divided revenue and a loads was average year. conversion which dollar when plasma quarter versus gross year, quarter, and at the Taking the we year, $X were our of centers second US look $X,XXX end at the for quarter. Third of plasma the XX.X% year same was up from QX by revenue revenue period ended rate, $X.X ago revenues increased centers the The month volume under $X,XXX last the million
business. pharma Turning to your the attention
million XXXX change $XXX,XXX compared termination December program of $X accounting quarter primarily program XXXX. one third of XXXX, increased revenues by of XXXX the the and in and Third April one in quarter year, estimate in the last driven to
period As period Mark given year, $XXX,XXX the we the mentioned, increased beyond. continue to pharma primarily good for XXXX into business win its due the and revenues and renew mandates to period prior the compared same in in momentum many Cost of new to both the profit increased the quarter plasma pharma for in revenue. year increase as to nature. the Gross of variable $X.X increase last and in due the in transaction the compared plasma to same are transactions costs plasma million
capabilities our to to business efficiently new continue investments We the significant $XXX,XXX. prepaid programs. year-over-year depreciation Thus, in grow to and and technological make XX.X% to the support launch us and increased give needed amortization business
our balance. any Regarding cash variants. positioned quarter well $X.X forecasts, our is exited impacts quarter further the on Based of we in the and from with $XXX,XXX zero company, of believe and ending from which debt, health and its to million COVID-XX weather capitalized we that remain second our cash unrestricted an increase we
thoughts to Lastly, updated where press for the have release XXXX. I your to want the our attention remainder of direct we
end of be XX%. a expect the the XX% $X.X to of full to million. For to continue to in to $X.X revenue million of range year, EBITDA increasing range total we our lower We're guidance to million reflecting $XX $XX the adjusted of growth million,
or in stock Our full for fourth turn margins slightly expenditures is the over for expected we out at and plasma operational that signed. I gross expected to year. like $X.X approximately increases operating to see pharma compensation to With flat to million the call have for continue expected to the at remain that This year for fourth is based amortization a and due be seasonal outlook increase expense approximately business year, profit during to the year. XX% million, in $XX.X Depreciation would expenses programs are questions-and-answers. expected million to Full roll we be we that least to sequential $XX.X the moderator quarter, full be with quarter. and incurred full new presumes the to the expense $X.X million recovery are expected
